Simcere Pharmaceutical Group Limited (FRA:S2P)
Germany · Delayed Price · Currency is EUR 1.250
+0.030 (2.46%)
At close: Jan 30, 2026
FRA:S2P Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 7,107 | 6,635 | 6,608 | 6,324 | 5,000 | 4,509 | |
Revenue Growth (YoY) | 12.10% | 0.41% | 4.49% | 26.49% | 10.89% | -10.48% |
Cost of Revenue | 1,350 | 1,311 | 1,624 | 1,327 | 1,080 | 899.93 |
Gross Profit | 5,756 | 5,325 | 4,984 | 4,997 | 3,920 | 3,609 |
Selling, General & Admin | 3,265 | 3,037 | 2,856 | 2,849 | 2,403 | 1,982 |
Research & Development | 1,476 | 1,410 | 1,563 | 1,728 | 1,417 | 1,142 |
Other Operating Expenses | -246.2 | -249.08 | -144.62 | -172.81 | -149.51 | -114.96 |
Operating Expenses | 4,491 | 4,191 | 4,273 | 4,390 | 3,686 | 3,009 |
Operating Income | 1,265 | 1,133 | 710.84 | 606.34 | 233.33 | 599.91 |
Interest Expense | -94.62 | -69.56 | -34.57 | -34.41 | -70.85 | -133.73 |
Interest & Investment Income | 40.36 | 39.23 | 54.96 | 59.87 | 68.29 | 26.25 |
Earnings From Equity Investments | 1.4 | 2.16 | 7.84 | 0.19 | -44.19 | -14.27 |
Currency Exchange Gain (Loss) | -8.13 | -20.87 | -13.28 | -57.22 | 116.01 | -46.23 |
EBT Excluding Unusual Items | 1,204 | 1,084 | 725.79 | 574.78 | 302.6 | 431.94 |
Gain (Loss) on Sale of Investments | -198.57 | -266.25 | -744.82 | 113.11 | 697.19 | 473.9 |
Gain (Loss) on Sale of Assets | 3.1 | 0.98 | 791.92 | -10.57 | 402.02 | -1.81 |
Asset Writedown | - | - | -6.87 | - | - | - |
Legal Settlements | -20.93 | 0.9 | -25.99 | - | - | - |
Other Unusual Items | - | - | - | 208.94 | - | -98.94 |
Pretax Income | 987.67 | 819.88 | 740.04 | 886.25 | 1,402 | 805.09 |
Income Tax Expense | 107.5 | 86.71 | 26.09 | -40.48 | -97.12 | 140.8 |
Earnings From Continuing Operations | 880.17 | 733.17 | 713.95 | 926.73 | 1,499 | 664.29 |
Minority Interest in Earnings | - | - | 0.81 | 4.14 | 8.18 | 5.25 |
Net Income | 880.17 | 733.17 | 714.76 | 930.87 | 1,507 | 669.53 |
Net Income to Common | 880.17 | 733.17 | 714.76 | 930.87 | 1,507 | 669.53 |
Net Income Growth | - | 2.57% | -23.22% | -38.23% | 125.10% | -33.29% |
Shares Outstanding (Basic) | 2,459 | 2,513 | 2,609 | 2,611 | 2,609 | 2,393 |
Shares Outstanding (Diluted) | 2,468 | 2,520 | 2,609 | 2,620 | 2,611 | 2,393 |
Shares Change (YoY) | -4.18% | -3.40% | -0.45% | 0.34% | 9.14% | 2.03% |
EPS (Basic) | 0.36 | 0.29 | 0.27 | 0.36 | 0.58 | 0.28 |
EPS (Diluted) | 0.36 | 0.29 | 0.27 | 0.36 | 0.58 | 0.28 |
EPS Growth | - | 7.41% | -24.26% | -38.29% | 106.46% | -34.61% |
Free Cash Flow | 1,038 | 1,034 | -332.13 | 1,011 | -411.46 | -256.11 |
Free Cash Flow Per Share | 0.42 | 0.41 | -0.13 | 0.39 | -0.16 | -0.11 |
Dividend Per Share | 0.160 | 0.160 | 0.160 | 0.160 | 0.150 | 0.150 |
Dividend Growth | - | - | - | 6.67% | - | - |
Gross Margin | 81.00% | 80.25% | 75.43% | 79.01% | 78.40% | 80.04% |
Operating Margin | 17.80% | 17.08% | 10.76% | 9.59% | 4.67% | 13.31% |
Profit Margin | 12.38% | 11.05% | 10.82% | 14.72% | 30.14% | 14.85% |
Free Cash Flow Margin | 14.61% | 15.59% | -5.03% | 15.99% | -8.23% | -5.68% |
EBITDA | 1,485 | 1,356 | 925.12 | 815.38 | 422.45 | 758.55 |
EBITDA Margin | 20.90% | 20.44% | 14.00% | 12.89% | 8.45% | 16.82% |
D&A For EBITDA | 219.97 | 223.17 | 214.29 | 209.04 | 189.12 | 158.63 |
EBIT | 1,265 | 1,133 | 710.84 | 606.34 | 233.33 | 599.91 |
EBIT Margin | 17.80% | 17.08% | 10.76% | 9.59% | 4.67% | 13.31% |
Effective Tax Rate | 10.88% | 10.58% | 3.52% | - | - | 17.49% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.